H1O Stock Chart & Stats
€0.43
€0.00(0.00%)
At close: 4:00 PM EDT
€0.43
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€0.43 - €0.43
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€12.23M
Enterprise Value€3.50M
Total Cash (Recent Filing)€8.80M
Total Debt (Recent Filing)€22.55K
Price to Earnings (P/E)―
Beta0.00
Next Earnings
Nov 24, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-38.80
Shares Outstanding7,018,528
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)3.04
Price to Sales (P/S)23.26
P/FCF Ratio-1.98
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€9.97Price Target Upside2218.20% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.6
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage And Recent Positive EquityVery low leverage and a return to positive equity provide durable financial flexibility. With minimal debt service the company can prioritize R&D, restructuring, or strategic deals without immediate interest burden, improving options for medium-term recovery and financing.
Healthy Gross Margin On Product EconomicsA near-50% gross margin indicates the core business generates meaningful unit economics. If operating costs are right-sized, these margins support sustainable profitability as revenue stabilizes, making recovery feasible without fundamentally changing the product mix.
Capital-structure Tightening And Strategic RepositioningShare-authority reduction can reduce future dilution and signal governance discipline. The planned Livechain/Humanyze repositioning into AI HR analytics is a structural strategic shift that could diversify revenue streams and access larger market opportunities if execution succeeds.
Bears Say
Sharp TTM Revenue DeclineA steep, recent revenue decline erodes scale and magnifies fixed-cost burdens. With a small revenue base this decline undermines the company's ability to leverage its healthy gross margins, increases per-unit overhead, and makes multi-quarter recovery challenging without new growth drivers.
Persistent Cash Burn And Negative Operating Cash FlowSustained negative operating and free cash flow depletes liquidity and forces recurring external financing or dilutive capital raises. Over a medium horizon this constrains strategic freedom, increases refinancing risk, and can interrupt product development or commercialization plans.
Multi-year Unprofitable Operations And Poor ROEConsistent multi-year negative profitability and negative ROE indicate the business has struggled to convert invested capital into returns. This structural weakness makes it harder to attract long-term capital and raises questions about the sustainability of current business models absent major operational change.
Vyome Holdings News
H1O FAQ
What was Vyome Holdings’s price range in the past 12 months?
Vyome Holdings lowest stock price was €0.43 and its highest was €0.43 in the past 12 months.
What is Vyome Holdings’s market cap?
Vyome Holdings’s market cap is €12.23M.
When is Vyome Holdings’s upcoming earnings report date?
Vyome Holdings’s upcoming earnings report date is Nov 24, 2026 which is in 114 days.
How were Vyome Holdings’s earnings last quarter?
Vyome Holdings released its earnings results on May 28, 2026. The company reported -€0.132 earnings per share for the quarter, the consensus estimate of -€0.132 by €0.
Is Vyome Holdings overvalued?
According to Wall Street analysts Vyome Holdings’s price is currently Undervalued.
Does Vyome Holdings pay dividends?
Vyome Holdings does not currently pay dividends.
What is Vyome Holdings’s EPS estimate?
Vyome Holdings’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Vyome Holdings have?
Vyome Holdings has 7,018,528 shares outstanding.
What happened to Vyome Holdings’s price movement after its last earnings report?
Vyome Holdings reported an EPS of -€0.132 in its last earnings report, expectations of -€0.132. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Vyome Holdings?
Currently, no hedge funds are holding shares in DE:H1O
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Vyome Holdings
Vyome Holdings, Inc. operates as a healthcare firm currently in its clinical development phase, concentrating on the creation of innovative medicinal treatments designed to address both immuno-inflammatory conditions and infrequent disorders. Founded in 2017, the company extends its market reach throughout the United States and into global territories, headquartered in Princeton, New Jersey.
H1O Stock 12 Month Forecast
Average Price Target
€9.97
▲(2218.20% Upside)